CN103897041A - Novel compound containing vancomycin structure and preparation method and use thereof - Google Patents

Novel compound containing vancomycin structure and preparation method and use thereof Download PDF

Info

Publication number
CN103897041A
CN103897041A CN201210595212.XA CN201210595212A CN103897041A CN 103897041 A CN103897041 A CN 103897041A CN 201210595212 A CN201210595212 A CN 201210595212A CN 103897041 A CN103897041 A CN 103897041A
Authority
CN
China
Prior art keywords
vancomycin
preparation
purposes
integer
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201210595212.XA
Other languages
Chinese (zh)
Inventor
杨子剑
杨静
高强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201210595212.XA priority Critical patent/CN103897041A/en
Publication of CN103897041A publication Critical patent/CN103897041A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a novel compound containing a vancomycin structure and a preparation method and use thereof. Compared with other forms of drugs or agents, the drug prepared from the novel compound containing the vancomycin structure has a better effect on treatment of an endophthalmitis disease.

Description

The new compound that contains vancomycin structure and preparation method and purposes
Technical field
The invention discloses the new compound that contains vancomycin structure and preparation method and the purposes of this compound.
Background technology
Vancomycin (Vancomycin, INN) is a kind of glycopeptide antibiotics, is used for prevention and the infection that causes for the treatment of gram-positive microorganism.Traditionally, vancomycin is used as " last first-line drug ", is used for treating all invalid severe infections of all microbiotic.
Endophthalmitis is a kind of inflammation of involving eyeball internal layer, vitreum, sclera, and most endophthalmitis are due to bacterium or fungi infestation.Bacterium route of infection can be wound, and the eyeball wound that operation causes can be also haematogenous (bacterium menses spread and cast to intraocular).The symptom of endophthalmitis is usually heavier, mainly contains ophthalmodynia, hyperemia, serious photophobia and eyesight and sharply declines.The symptom of endophthalmitis is usually heavier, mainly contains ophthalmodynia, hyperemia, serious photophobia and eyesight and sharply declines.
The new compound that contains vancomycin of preparing at this patent directly wraps up the nanometer formulation that vancomycin makes and compares with polymkeric substance is simple when endophthalmitis in treatment, the medicine that this patent is invented medication effect in the time of the eye disease model for the treatment of endophthalmitis and severe infections is very good, and effect far surmounts the nanometer formulation of the simple directly parcel of polymkeric substance vancomycin.
Summary of the invention
Of the present invention theing contents are as follows:
The segmented copolymer that the invention discloses the vancomycin coupling shown in following formula I, its structure is as follows:
Figure BSA00000835332600021
Wherein PEG refers to polyoxyethylene glycol, specifically finger-C 2h 4(OC 2h 4) W-, the wherein integer between W=1-500, molecular weight is about 100-21000, the preferred 1-300 of w, molecular weight is preferably about 100-13000; Integer between n=1-200; The preferably integer between n=1-100.
The preparation method of multipolymer of the present invention, is characterized in that:
1) obtain compd A with methoxy poly (ethylene glycol) amine and citric acid reactions;
2) reaction of the sebacic acid of compd A and ethanoyl obtains polymer B, the wherein integer of n=1-200, preferably 1-100;
3) polymer B is reacted and is obtained final product with vancomycin C;
Figure BSA00000835332600022
compd A;
Figure BSA00000835332600031
Polymer B;
Figure BSA00000835332600032
Vancomycin C
Wherein vancomycin C is purchased.The required solvent of described chemical step of the final product of the synthetic new compound that contains vancomycin is selected from: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
The compound of new system can be prepared into the nanometer formulation that is suitable for topical, microball preparation.Purposes is the medicine of preparation treatment endophthalmitis.
Preparation method of the present invention is specific as follows:
1) sebacic acid is refluxed in diacetyl oxide, form ethanoyl-sebacic acid;
2) methoxy poly (ethylene glycol) amine and citric acid are dissolved in solvent, and hybrid reaction is spent the night, the dry compd A that obtains;
3) ethanoyl-sebacic acid is mixed to reaction at 100-200 DEG C, reaction times 10min to 10h with compd A; After question response mixture is cooling, washing, the dry polymer B that obtains;
4) by vancomycin C and polymer B as for 1-96 hour in solvent, after ultrasonic reaction 1-30 minute, in baking oven, foster and obtain formula I polymkeric substance, then homogenizer high-speed stirring 1-10 minute in subzero 30 DEG C of 0-, rotation volatilization obtains crude product, and aftertreatment obtains the nanometer formulation of end product formula I polymkeric substance.
Its reaction equation is as follows:
Figure BSA00000835332600041
Figure BSA00000835332600051
The polymkeric substance that what the present invention obtained contain vancomycin structure, is easy to dissolve in water, and its transformation period extend much than vancomycin, such new compound effect in the time of the model for the treatment of endophthalmitis is splendid.
The nanometer formulation that the end product of preparing at this patent is made treatment eye disease relatively in, the medication effect of this patent new compound is very good, surmounts the nanometer formulation that is directly wrapped up vancomycin (not with vancomycin coupling) by polymkeric substance completely.
Brief description of the drawings:
The nuclear magnetic resonance map of the end product of Fig. 1 embodiment 1.
Nanoparticle, the sebacic acid-glycol copolymer that Fig. 2 embodiment 1 makes directly wraps up medicine accumulative releasing degree and the time chart of vancomycin nanoparticle and vancomycin ordinary preparation.
Embodiment
Specific embodiment is described in further detail the present invention below, but the present invention not only limits to following examples.Preparation Example is as follows:
Embodiment 1
1) mixture of sebacic acid 50g in 500ml diacetyl oxide refluxes, to form ethanoyl-sebacic acid;
2) methoxy poly (ethylene glycol) amine 6.5g, citric acid 73mg, dicyclohexylcarbodiimide 168mg and pyridine 8.2mg mix and add 32ml methylene dichloride, at room temperature stir and spend the night; Then wash with ether, and dry under vacuum, obtain polymkeric substance;
3) by the 1st) step and the 2nd) step Product mix puts into flask, and at 180 DEG C, decompression contains intermingle with reaction 1 hour; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and also dry by petroleum ether;
4) the 800mg polymkeric substance of 150mg vancomycin and step 3 is put into the dichloromethane solution 48 hours of 8ml dimethyl sulfoxide (DMSO) and 12ml; Ultrasonic 5 minutes; Then insert in baking oven 1 hour; In subzero 10-20 degree, homogenizer ultra-high speed stirs 3 minutes, then puts into 2% polyvinyl alcohol solution 600 and turns and stir 3 hours; Freeze-drying after centrifugal collection, obtains the nanoparticle of end product.
Embodiment 2
1) methoxy poly (ethylene glycol) amine 3g, citric acid 45mg, dicyclohexylcarbodiimide 200mg and pyridine 6mg mix and add 20ml methylene dichloride, at room temperature stir and spend the night; Then wash with ether, and dry under vacuum;
2) ethanoyl-sebacic acid 20g (being purchased) and the 1st step Product mix are put into flask, at 170 DEG C, react 1.5 hours; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and with petroleum ether the dry polymkeric substance (structure or with homemade slightly different, molecular weight or different because being purchased quality) that obtains;
3) 30mg vancomycin and this polymkeric substance 150mg are put into the solution being mixed by 1ml methyl alcohol and 1ml methylene dichloride; Ultrasonic 2 minutes; Then insert in baking oven 24 hours; In subzero 10-20 degree, homogenizer high-speed stirring 2 minutes, product is put into 3% cholic acid solution 600 and is turned and stir 4 hours; Freeze-drying after centrifugal collection, obtains the microballoon of new compound.
Effect experiment is as follows:
Sample prepared by embodiment 1-2 and and sebacic acid-glycol copolymer directly the nanoparticle medicine group of the vancomycin of parcel (there is not chemical coupling reaction, vancomycin does not have structural changes), vancomycin ordinary preparation (powder injection) carries out respectively the drug action test of stability test, drug release in vitro test and endophthalmitis.
Stability test:
By the nanoparticle medicine group of the vancomycin of 1 group of sample of preparing of embodiment and sebacic acid-glycol copolymer parcel, vancomycin ordinary preparation is got with amount (in vancomycin) and is measured respectively absorbance.Then put into 20 degree incubator 3 months for three groups, take out subsequently and measure 280 nanometer absorbances, the absorbance front and back of the vancomycin of the visible embodiment 1-2 group of result and ordinary preparation group are without changing, and the nanoparticle group absorbancy of parcel decline 26%.Drug release in vitro test:
By 1 group of embodiment, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the vancomycin of parcel and vancomycin ordinary preparation component have another name called get equivalent medicine (in vancomycin, every group containing 10mg vancomycin), then by each group of medicine as in test tube, after soaking with PBS damping fluid, 37 degrees Celsius of lower joltings in shaking table, after timing sampling, under ultraviolet spectrophotometer, measure the content of medicine, and the medicament contg per-cent that after record, calculating discharges, do releasing curve diagram, X-coordinate be the time (my god), ordinate zou is the per-cent discharging.See Fig. 2, the medicine that visible embodiment discharges is more permanent, makes drug half-life longer.
Solubility test in water:
By embodiment 1-2 group, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the vancomycin of parcel and vancomycin ordinary preparation component have another name called get equivalent medicine (in vancomycin, every group containing 100mg vancomycin), put into respectively test tube, with the dissolving of 10mlPBS damping fluid jolting, situation is dissolved in static rear observation.The dissolved state that records 3 minutes and 20 minutes, result is as follows.
The comparison of table 1 solubleness
Figure BSA00000835332600081
The therapeutic action of medicine to eye inflammation
1 laboratory animal
Healthy Wistar rat, male and female are not limit, and body weight is at 220g, observes intraocular in good condition and carry out this test without other eye illness person under slit lamp.
2 experimental techniques
2.1 modeling method
Carry out eyeground trauma infection contamination model, rat sucks etherization, on simple fixing and mouse plate, uses ophthalmology micro-surgical instrument on right eye temporo centered by 10 positions after elongation limbus of sclera 2 millimeters, does the arc incision parallel with corneoscleral junction, is about 3.0mm.Cut wall of eyeball holostrome, deeply reach vitreous space.Incision causes pigmented film incarceration, and pigmented film exposed parts is parallel with cutting edge, and otch will not be sewed up, and allows it produce and infects.
2.2 clustering method
Modeling success laboratory animal is divided into model group, embodiment 1-2 group, vancomycin ordinary preparation group at random, polymkeric substance directly wraps up nanoparticle subgroup prepared by vancomycin, the equal intravitreal 50 μ l medicines of each group, model group gives isopyknic PBS solution.
3 inspection items and method
Conventional fundoscopy
Every daily slit lamp, indirect ophthalmoscope inspection.After intervening, each treated animal was carried out to the scoring of endophthalmitis clinical scale in 1,4,7 day, primary part observation anterior chamber scintillation, aqueous cell and vitreous opacity degree, its grade scale is that (inflammatory exudate enters aqueous humor in anterior chamber's scintillation classification, under the narrow light belt of slit lamp casts oblique rays on, visible light flash and ooze out particle float, this phenomenon is called aqueous flare): 0 grade, without aqueous flare (light beam is transparent shinny); 1 grade, slight aqueous flare (the faint light beam that turns white); 2 grades, moderate aqueous flare (the milky white light beam of moderate can be distinguished iris and lens details); 3 grades, significantly aqueous flare (obvious milky white light beam, impalpable iris and lens details); 4 grades, serious anterior chamber's scintillation, aqueous humor becomes curdled appearance, with a large amount of fibrinous exudates.
4 statistical procedures
Data represent with x ± s, t inspection between relatively employing group between two groups.P < 0.05, for there being significant difference, has statistical significance.
5 results
Clinical inflammation scoring
24h after sudden and violent leakage wound, there is palpebral edema in all rats, and corneal edema is obvious, and conjunctiva is congested, oedema obviously, anterior chamber's scintillation (+), exudation of anterior chamber (+).After intervening, within 4,7 days, carry out clinical inflammation scoring, model group inflammatory symptom increases the weight of day by day, and treatment group laboratory animal cornea is all transparent gradually, and anterior chamber's scintillation alleviates gradually, oozes out and is tending towards absorbing, and vitreous opacity alleviates in various degree.Each treatment group and model group more all have significant difference (table 1).
The clinical inflammation scoring of the each group of the postoperative different time points of table 1 situation (n > 10x ± s)
Figure BSA00000835332600091
With relatively * p < 0.05 of model group, * * p < 0.01.

Claims (9)

1. in the structure being shown below, contain the segmented copolymer of vancomycin, its structure is as follows:
Figure FSA00000835332500011
2. the multipolymer of claim 1, wherein PEG refers to polyoxyethylene glycol, specifically finger-C 2h 4(OC 2h 4) W-, the wherein integer between W=1-500, molecular weight is 100-21000, the preferred 1-300 of w, the integer between n=1-200; The preferably integer between n=1-100.
3. the preparation method of multipolymer as claimed in claim 1, is characterized in that:
1) obtain compd A with methoxy poly (ethylene glycol) amine and citric acid reactions;
2) reaction of the sebacic acid of compd A and ethanoyl obtains polymer B, the wherein integer of n=1-200, preferably 1-100;
3) polymer B is reacted and is obtained final product with vancomycin C;
Figure FSA00000835332500012
compd A;
Figure FSA00000835332500021
Polymer B;
Figure FSA00000835332500022
Vancomycin C.
4. the method for claim 3, wherein said chemical step 1-3 selects solvent to be selected from: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
5. the compound of claim 1 can be prepared into the nanometer formulation that is suitable for topical, microball preparation.
6. described in claim 5, part is intravitreal injection administration, dosing eyes.
7. the purposes of the compound of claim 1, purposes is the medicine of preparation treatment eye disease.
8. the purposes of the compound of claim 1, purposes is the medicine of preparation treatment ocular infection.
9. the purposes of claim 7, wherein eye disease refers to endophthalmitis.
CN201210595212.XA 2012-12-24 2012-12-24 Novel compound containing vancomycin structure and preparation method and use thereof Pending CN103897041A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210595212.XA CN103897041A (en) 2012-12-24 2012-12-24 Novel compound containing vancomycin structure and preparation method and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210595212.XA CN103897041A (en) 2012-12-24 2012-12-24 Novel compound containing vancomycin structure and preparation method and use thereof

Publications (1)

Publication Number Publication Date
CN103897041A true CN103897041A (en) 2014-07-02

Family

ID=50988652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210595212.XA Pending CN103897041A (en) 2012-12-24 2012-12-24 Novel compound containing vancomycin structure and preparation method and use thereof

Country Status (1)

Country Link
CN (1) CN103897041A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192690A (en) * 1995-07-31 1998-09-09 蛋白传递公司 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
WO2007016380A2 (en) * 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192690A (en) * 1995-07-31 1998-09-09 蛋白传递公司 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
WO2007016380A2 (en) * 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate

Similar Documents

Publication Publication Date Title
JP6882186B2 (en) Methods for sunitinib preparations and their use in the treatment of eye disorders
US20100222308A1 (en) Ophthalmic, otic or nasal pharmaceutical composition and the use thereof
Xu et al. Ocular biocompatibility and tolerance study of biodegradable polymeric micelles in the rabbit eye
Buzard et al. Two cases of toxic anterior segment syndrome from generic trypan blue
CN103897174A (en) Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof
Lu et al. Centrifugally concentric ring-patterned drug-loaded polymeric coating as an intraocular lens surface modification for efficient prevention of posterior capsular opacification
CN103833998A (en) Novel compound with ethacrynic acid structure as well as preparation method and application of novel compound
KR20160033213A (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
CN103142468A (en) Tacrolimus eye ointment for cornea transplantation and preparation method thereof
Yadav et al. Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Liu et al. Optimization of subconjunctival biodegradable microfilms for sustained drug delivery to the anterior segment in a small animal model
KR20190109604A (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
CN103848852A (en) New compound containing cephalosporin structure as well as preparation method and application thereof
CN103848901A (en) New compound containing vancomycin structure as well as preparation method and application thereof
CN103848894A (en) Novel compound containing daptomycin structure as well as preparation method and application thereof
CN103897041A (en) Novel compound containing vancomycin structure and preparation method and use thereof
CN103910868A (en) Nonlinear polymer having doxorubicin structure, and preparation method and application thereof
CN103910867A (en) Nonlinear polymer having doxorubicin structure, and preparation method and application thereof
Krenzer et al. Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits
TW200918075A (en) Compositions and methods for modulating endophthalmitis using fluoroquinolones
CN103910873A (en) Doxorubicin structure-containing star-shaped polymer and preparation method and use thereof
CN103865056A (en) Nonlinear polymer containing doxorubicin structure, and preparation method and application thereof
CN103910872A (en) Doxorubicin structure-containing star-shaped polymer and preparation method and use thereof
CN103848985A (en) Novel compound containing sunitinib analogue structure as well as preparation method and application thereof
Goecks et al. Toxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140702